Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs GLENMARK PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES GLENMARK PHARMA DIVIS LABORATORIES/
GLENMARK PHARMA
 
P/E (TTM) x 29.6 13.3 222.2% View Chart
P/BV x 7.6 1.3 569.9% View Chart
Dividend Yield % 0.9 0.6 153.2%  

Financials

 DIVIS LABORATORIES   GLENMARK PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-22
GLENMARK PHARMA
Mar-22
DIVIS LABORATORIES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs5,425691 785.5%   
Low Rs3,562416 857.1%   
Sales per share (Unadj.) Rs337.5436.1 77.4%  
Earnings per share (Unadj.) Rs111.535.2 316.7%  
Cash flow per share (Unadj.) Rs123.352.5 234.9%  
Dividends per share (Unadj.) Rs30.002.50 1,200.0%  
Avg Dividend yield %0.70.5 147.7%  
Book value per share (Unadj.) Rs441.8321.4 137.4%  
Shares outstanding (eoy) m265.47282.17 94.1%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x13.31.3 1,049.7%   
Avg P/E ratio x40.315.7 256.5%  
P/CF ratio (eoy) x36.510.5 345.8%  
Price / Book Value ratio x10.21.7 591.1%  
Dividend payout %26.97.1 378.9%   
Avg Mkt Cap Rs m1,192,890156,067 764.3%   
No. of employees `000NANA-   
Total wages/salary Rs m9,46224,474 38.7%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m89,598123,049 72.8%  
Other income Rs m1,1591,667 69.5%   
Total revenues Rs m90,757124,716 72.8%   
Gross profit Rs m38,81120,594 188.5%  
Depreciation Rs m3,1154,867 64.0%   
Interest Rs m202,981 0.7%   
Profit before tax Rs m36,83514,412 255.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,2314,476 161.5%   
Profit after tax Rs m29,6059,936 297.9%  
Gross profit margin %43.316.7 258.8%  
Effective tax rate %19.631.1 63.2%   
Net profit margin %33.08.1 409.2%  
BALANCE SHEET DATA
Current assets Rs m96,10482,823 116.0%   
Current liabilities Rs m24,54446,894 52.3%   
Net working cap to sales %79.929.2 273.5%  
Current ratio x3.91.8 221.7%  
Inventory Days Days96 134.8%  
Debtors Days Days98792 1,073.4%  
Net fixed assets Rs m50,08771,148 70.4%   
Share capital Rs m531282 188.1%   
"Free" reserves Rs m116,75190,421 129.1%   
Net worth Rs m117,28290,703 129.3%   
Long term debt Rs m025,717 0.0%   
Total assets Rs m146,191153,972 94.9%  
Interest coverage x1,842.85.8 31,582.1%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.8 76.7%   
Return on assets %20.38.4 241.5%  
Return on equity %25.211.0 230.4%  
Return on capital %31.414.9 210.3%  
Exports to sales %00-   
Imports to sales %19.70-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m17,676NA-   
Fx inflow Rs m78,44532,142 244.1%   
Fx outflow Rs m17,95313,482 133.2%   
Net fx Rs m60,49218,660 324.2%   
CASH FLOW
From Operations Rs m19,11811,087 172.4%  
From Investments Rs m-21,949-3,333 658.6%  
From Financial Activity Rs m-5,324-5,205 102.3%  
Net Cashflow Rs m-8,1562,724 -299.4%  

Share Holding

Indian Promoters % 51.9 46.7 111.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 36.2 34.1 106.2%  
FIIs % 15.4 23.1 66.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 48.1 53.4 90.1%  
Shareholders   379,257 313,540 121.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SUN PHARMA    DR. REDDYS LAB    CIPLA    LUPIN    AUROBINDO PHARMA    


More on Divis Laboratories vs Glenmark Pharma

No comparison is complete without understanding how the stock prices have performed over a period of time.

Here's a brief comparison:

Divis Laboratories vs Glenmark Pharma Share Price Performance

Period Divis Laboratories Glenmark Pharma S&P BSE HEALTHCARE
1-Day 1.11% 1.63% 0.33%
1-Month -7.18% 6.21% 0.28%
1-Year -30.23% -19.46% -6.55%
3-Year CAGR 23.73% 6.86% 20.31%
5-Year CAGR 26.30% -6.32% 10.96%

* Compound Annual Growth Rate

Here are more details on the Divis Laboratories share price and the Glenmark Pharma share price.

Moving on to shareholding structures...

The promoters of Divis Laboratories hold a 51.9% stake in the company. In case of Glenmark Pharma the stake stands at 46.7%.

To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Divis Laboratories and the shareholding pattern of Glenmark Pharma.

Finally, a word on dividends...

In the most recent financial year, Divis Laboratories paid a dividend of Rs 30.0 per share. This amounted to a Dividend Payout ratio of 26.9%.

Glenmark Pharma paid Rs 2.5, and its dividend payout ratio stood at 7.1%.

You may visit here to review the dividend history of Divis Laboratories, and the dividend history of Glenmark Pharma.

For a sector overview, read our pharmaceuticals sector report.



Today's Market

Sensex Today Ends 21 Points Higher | BHEL, RVNL Surge 10% to Hit 52-Week High | Why PNB Share Price is Rising(Closing)

Indian share markets traded in a rangebound manner throughout today's session to end flat.